tradingkey.logo

Trinity Biotech PLC

TRIB
1.020USD
-0.260-20.31%
收盘 12/24, 13:00美东报价延迟15分钟
8.46M总市值
亏损市盈率 TTM

Trinity Biotech PLC

1.020
-0.260-20.31%

关于 Trinity Biotech PLC 公司

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Trinity Biotech PLC简介

公司代码TRIB
公司名称Trinity Biotech PLC
上市日期Oct 21, 1992
CEOGillard (John)
员工数量- -
证券类型Depository Receipt
年结日Oct 21
公司地址Ida Business Park, Bray, Co Wicklow
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Ireland
邮编18
电话01135312955111
网址https://www.trinitybiotech.com/
公司代码TRIB
上市日期Oct 21, 1992
CEOGillard (John)

Trinity Biotech PLC公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
地区USD
名称
营收
占比
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
业务
地区
业务USD
名称
营收
占比
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

股东统计

更新时间: 11月21日 周五
更新时间: 11月21日 周五
持股股东
股东类型
持股股东
持股股东
占比
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
持股股东
持股股东
占比
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
股东类型
持股股东
占比
Corporation
60.06%
Private Equity
48.04%
Investment Advisor
3.34%
Hedge Fund
1.33%
Research Firm
0.14%
Investment Advisor/Hedge Fund
0.13%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
2023Q2
47
3.98M
52.08%
+190.03K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
MiCo IVD Holdings, LLC
447.59K
2.4%
--
--
Dec 17, 2024
Perceptive Advisors LLC
358.00K
1.92%
+358.00K
--
Jun 30, 2025
Hunter Associates Investment Management LLC
87.58K
0.47%
+12.56K
+16.74%
Jun 30, 2025
Renaissance Technologies LLC
11.39K
0.06%
-3.94K
-25.70%
Jun 30, 2025
Two Sigma Investments, LP
3.02K
0.02%
-3.51K
-53.79%
Jun 30, 2025
Moss Adams Wealth Advisors LLC
5.13K
0.03%
--
--
Jun 30, 2025
Cambridge Investment Research Advisors, Inc.
4.46K
0.02%
--
--
Jun 30, 2025
Raymond James & Associates, Inc.
5.07K
0.03%
--
--
Jun 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
公告日期
类型
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1

常见问题

Trinity Biotech PLC的前五大股东是谁?

Trinity Biotech PLC 的前五大股东如下:
MiCo IVD Holdings, LLC持有股份:447.59K,占总股份比例:2.40%。
Perceptive Advisors LLC持有股份:358.00K,占总股份比例:1.92%。
Hunter Associates Investment Management LLC持有股份:87.58K,占总股份比例:0.47%。
Renaissance Technologies LLC持有股份:11.39K,占总股份比例:0.06%。
Two Sigma Investments, LP持有股份:3.02K,占总股份比例:0.02%。

Trinity Biotech PLC的前三大股东类型是什么?

Trinity Biotech PLC 的前三大股东类型分别是:
MiCo IVD Holdings, LLC
Perceptive Advisors LLC
Hunter Associates Investment Management LLC

有多少机构持有Trinity Biotech PLC(TRIB)的股份?

截至2025Q3,共有51家机构持有Trinity Biotech PLC的股份,合计持有的股份价值约为972.36K,占公司总股份的12.90%。与2025Q2相比,机构持股有所增加,增幅为-4.08%。

哪个业务部门对Trinity Biotech PLC的收入贡献最大?

在FY2023,Clinical Laboratory业务部门对Trinity Biotech PLC的收入贡献最大,创收42.29M,占总收入的74.41%。
KeyAI